AnHeart Therapeutics Co., Ltd. (“AnHeart”) is a clinical stage biopharmaceutical company developing novel oncology therapies. AnHeart is headquartered in Hangzhou, China with offices in Beijing, Shanghai and has a subsidiary AnHeart Therapeutics Inc. in New York. Formed in November 2018, AnHeart is currently managed by biopharmaceuticals industry veterans and financially backed by venture capital funds.